From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK

IF 2.4 Q3 GASTROENTEROLOGY & HEPATOLOGY Frontline Gastroenterology Pub Date : 2024-07-13 DOI:10.1136/flgastro-2024-102710

Oliver D Tavabie, Yvanne Enever, Daniel Green, Helen Crisp, Emmanouil Tsochatzis, Amir Gander, Dina Mansour, Vanessa Hebditch, Julie Adams, Adam Ashbourn, Christopher Mysko, Richard Allen, Laura Kent, James B Maurice, Ankur Srivastava, Abhishek Chauhan, Tom Johnston, Janet Ruane, Rebecca Varni, Caroline Fletcher, Cyril Sieberhagen, Gordon Hay, Giovanna Bretland, Maggie Corrigan, Francesco Ferraro, Riley McMahon, Trudie Burge, Harry Ferguson, Louise Jennings, Brian Hogan, Andrew Cook, Rajiv Jalan, Gautam Mehta

{"title":"From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK","authors":"Oliver D Tavabie, Yvanne Enever, Daniel Green, Helen Crisp, Emmanouil Tsochatzis, Amir Gander, Dina Mansour, Vanessa Hebditch, Julie Adams, Adam Ashbourn, Christopher Mysko, Richard Allen, Laura Kent, James B Maurice, Ankur Srivastava, Abhishek Chauhan, Tom Johnston, Janet Ruane, Rebecca Varni, Caroline Fletcher, Cyril Sieberhagen, Gordon Hay, Giovanna Bretland, Maggie Corrigan, Francesco Ferraro, Riley McMahon, Trudie Burge, Harry Ferguson, Louise Jennings, Brian Hogan, Andrew Cook, Rajiv Jalan, Gautam Mehta","doi":"10.1136/flgastro-2024-102710","DOIUrl":null,"url":null,"abstract":"Developing new treatments that improve outcomes for patients with decompensated cirrhosis remains an unmet area of clinical need. The UK has a rich history of being on the forefront of clinical trials for this patient group. However, there have been challenges in achieving this goal in the past decade, with several negative studies as well as trials struggling to achieve recruitment. This has been further exacerbated by the changed clinical landscape following the COVID-19 pandemic. In response to this, the O’Shaughnessy report was commissioned to identify potential opportunities to improve clinical trial performance in the UK. In this review article, we identify critical areas for the UK hepatology community to collaborate and develop sustainable partnerships for clinical trial delivery which will ensure that outcomes are representative, inclusive and patient-centred.","PeriodicalId":46937,"journal":{"name":"Frontline Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontline Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/flgastro-2024-102710","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Developing new treatments that improve outcomes for patients with decompensated cirrhosis remains an unmet area of clinical need. The UK has a rich history of being on the forefront of clinical trials for this patient group. However, there have been challenges in achieving this goal in the past decade, with several negative studies as well as trials struggling to achieve recruitment. This has been further exacerbated by the changed clinical landscape following the COVID-19 pandemic. In response to this, the O’Shaughnessy report was commissioned to identify potential opportunities to improve clinical trial performance in the UK. In this review article, we identify critical areas for the UK hepatology community to collaborate and develop sustainable partnerships for clinical trial delivery which will ensure that outcomes are representative, inclusive and patient-centred.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

从奥萧纳西到机遇：英国肝病学试验的创新之路

开发改善失代偿期肝硬化患者预后的新疗法仍是一个尚未满足临床需求的领域。英国在针对这一患者群体的临床试验方面有着丰富的经验。然而，在过去的十年中，要实现这一目标却面临着挑战，有几项研究效果不佳，还有一些试验招募困难重重。COVID-19 大流行后，临床环境发生了变化，进一步加剧了这一问题。为此，英国委托奥萧纳西（O'Shaughnessy）编写了一份报告，以确定提高英国临床试验绩效的潜在机会。在这篇综述文章中，我们确定了英国肝病学界合作的关键领域，并为临床试验的实施建立了可持续的合作伙伴关系，这将确保试验结果具有代表性、包容性并以患者为中心。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontline Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

4.70

自引率

11.50%

发文量

期刊介绍： Frontline Gastroenterology publishes articles that accelerate adoption of innovative and best practice in the fields of gastroenterology and hepatology. Frontline Gastroenterology is especially interested in articles on multidisciplinary research and care, focusing on both retrospective assessments of novel models of care as well as putative future directions of best practice. Specifically Frontline Gastroenterology publishes articles in the domains of clinical quality, patient experience, service provision and medical education.